Gene Expression Signatures Associated with Prior Rituximab Treatment in Patients with Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the CHAMPION-NMOSD Trial

Latent Class Analysis (LCA) of Treatment Preferences Among Adults with Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States

Quantifying the Lifetime Health and Societal Benefits from Earlier Diagnosis and Access to Approved Targeted Immunotherapies in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States